Carvedilol Tablets 25 mg Recalled Due to Impurity Above Acceptable Limit
Glenmark Pharmaceuticals is recalling Carvedilol Tablets USP 25 mg nationwide due to the presence of N-Nitroso Carvedilol I impurity above the recommended acceptable intake limit, resulting from CGMP deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a potential health hazard (N-Nitroso impurity, a known carcinogen class) without reported illnesses. The hazard is a manufacturing deviation leading to a documented impurity above acceptable limits, which meets the Severe threshold for Class II recalls with identified risk.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Carvedilol Tablets USP 25 mg, 500-Count bottles (NDC 68462-165-05) manufactured for distribution nationwide. The recall is due to the presence of N-Nitroso Carvedilol I impurity above the recommended acceptable intake limit, which resulted from Current Good Manufacturing Practice (CGMP) deviations.
Affected lots include Lots 19231107, 19231114, and 19231152 with expiration date February 2025, and Lot 19234866 with expiration date January 2026. A total of 18,696 bottles have been distributed.
Consumers who have this medication should contact their pharmacist or healthcare provider for guidance. Do not stop taking the medication without consulting a healthcare professional, as abrupt discontinuation may be harmful. Patients should return unused product to their pharmacy.
The recalled product
- Product
- CARVEDILOL (CARVEDILOL)
- Brand
- CARVEDILOL
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription Medication
- Affected units
- 18,696
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot
- expiry: Lots 19231107
- 19231114
- 19231152
- Exp Feb-25
- Lot 19234866
- Exp Jan-26
UPCs (4)
- 0368462162019
- 0368462163016
- 0368462164013
- 0368462165010
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · CARVEDILOL
- HighMajor Pharmaceuticals carvedilol tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-27
- HighCarvedilol 12.5 mg tablets recalled over nitrosamine above acceptable intake level
FDA (Drugs) · 2025-08-20
- HighGlenmark carvedilol 12.5 mg tablets exceed the nitrosamine impurity limit
FDA (Drugs) · 2025-08-20
- HighCarvedilol 3.125 mg tablets recalled for nitrosamine impurity above intake limit
FDA (Drugs) · 2025-08-20
- HighCarvedilol 25 mg tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-20
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08